Immunocytochemical utility of claudin‐4 versus those of Ber‐EP4 and MOC‐31 in effusion cytology

Recently, claudin‐4 (CL4) immunocytochemistry was reported to be useful for differential diagnosis in effusion cytology. We wondered whether CL4 might be useful for “single‐shot” identification of metastatic carcinoma. The purpose of this study was to evaluate the usefulness of CL4 in effusion cytology.

[1]  Mitra Heidarpour,et al.  Diagnostic value of claudin-4 marker in pleural and peritoneal effusion cytology: Does it differentiate between metastatic adenocarcinoma and reactive mesothelial cells? , 2014, Advanced biomedical research.

[2]  G. Pinkus,et al.  Claudin‐4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology , 2014, Cancer cytopathology.

[3]  Z. Tabatabai,et al.  The Diagnostic Utility of D2-40, Calretinin, CK5/6, Desmin and MOC-31 in the Differentiation of Mesothelioma from Adenocarcinoma in Pleural Effusion Cytology , 2012, Acta Cytologica.

[4]  B. Xie,et al.  Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry , 2011, Diagnostic cytopathology.

[5]  S. Lonardi,et al.  Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions , 2011, Diagnostic cytopathology.

[6]  A. Gown,et al.  Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. , 2009, Archives of pathology & laboratory medicine.

[7]  P. Morin,et al.  The claudins , 2009, Genome Biology.

[8]  S. Masood,et al.  Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: The utility of immunocytochemical panel in the differential diagnosis , 2009, Diagnostic cytopathology.

[9]  J. Lee,et al.  Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks , 2009, Diagnostic cytopathology.

[10]  D. Coffey,et al.  Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology? , 2009, Archives of pathology & laboratory medicine.

[11]  C. Michael,et al.  Utility of WT‐1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions , 2008, Diagnostic cytopathology.

[12]  B. Murer,et al.  Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions , 2007, Virchows Archiv.

[13]  S. Pradhan,et al.  Cytology of body fluids from different sites: an approach for early diagnosis of malignancy. , 2006, JNMA; journal of the Nepal Medical Association.

[14]  C. Kandaraki,et al.  Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids , 2005, Diagnostic cytopathology.

[15]  M. Lozano,et al.  Immunocytochemistry in the differential diagnosis of serous effusions , 2001, Cancer.

[16]  A. Berner,et al.  Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies , 1999, Virchows Archiv.

[17]  I. Ramzy,et al.  Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1. , 1996, Acta cytologica.

[18]  P. Devine,et al.  Markers for metastatic adenocarcinoma in serous effusion specimens , 1994, Diagnostic cytopathology.

[19]  D. Whitaker,et al.  Monoclonal antibody Ber‐EP4: Its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens , 1994, Diagnostic cytopathology.